What is sum-of-the-parts valuation?

What is sum-of-the-parts valuation?

A sum-of-the-parts valuation, or SOTP, values a company by breaking it into separate businesses. You value each business on its own, then add them up. That total is the company's worth. It works best for conglomerates.

Think of a big company as a bundle of smaller companies. Each piece may have a different growth rate, risk, or profit, so SOTP values each piece on its own. A tech arm and a real estate arm each need a separate model. Sum the values to get the whole.

How do you do a sum-of-the-parts valuation?

First, list every business segment. Public companies report segments in their filings; if they don't, you dig into the numbers yourself. You need a clear breakdown of revenue and profit.

Next, pick a method for each piece: discounted cash flow for stable businesses, trading multiples for fast movers. Add the segment values to get enterprise value, then subtract net debt and non-operating liabilities, add non-operating assets, and divide by shares outstanding to get price per share.

When should you use SOTP?

Use SOTP for conglomerates with many different businesses, like General Electric or Amazon. Their divisions trade at different multiples, and a single company-wide multiple hides the truth, so you cannot see which pieces are cheap and which are expensive.

Skip SOTP for a single-line business where one product makes up almost all revenue. Also skip it if the company does not disclose segments, since you cannot value what you cannot see.

When does SOTP apply to biotech companies?

SOTP also earns its keep in biotech. Clinical-stage, pre-revenue companies own a pipeline of drug assets, and most sell nothing yet. A single company-wide multiple means nothing with no revenue to multiply. So you value each therapeutic asset on its own.

Each drug gets its own set of assumptions. You estimate the market size the drug could serve, the peak opportunity in revenue it could capture, and the uptake curve after launch. Weight those by the odds it reaches market, and you get a risk-adjusted value.

The probability of success through FDA trials is the heart of it. An asset deep in clinical trials has a far higher chance of approval than one still in the lab, so it is worth more. Early-stage drugs are riskier and priced at a steeper discount.

Add up what each drug is worth, and the sum is the whole company. Biotech firms trade on this pipeline math, not on today's sales, because today's sales are near zero. That makes SOTP the standard lens for pre-revenue pharma, not a fringe tool.

Why does a conglomerate trade below its parts?

The gap between the whole and the parts has a name: the conglomerate discount. Investors routinely price a company below the value of its separate businesses. One reason is simplicity. Focused firms are easier to understand, so they earn a higher multiple.

That is why you are looking for a discount, not a premium. Mixing unrelated businesses adds management layers and overhead. Each division may fight for capital that a single-minded firm would deploy better. The market hates complexity it cannot price.

Treat the output as a range, not a truth. Segment figures are estimates drawn from the company's own assumptions. Managers can shift costs between divisions to flatter a weaker one. So check who is reporting the numbers before you trust them.

A break-up rarely happens by itself. Activists push for it, or a buyer assembles the pieces and sells them off. Until a catalyst appears, deep value may stay on paper. That patience is the price of acting on hidden value.

How does SOTP defend against a takeover?

A hostile takeover bidder wants your company cheap. SOTP gives the board a piece-by-piece number to hold against the offer. If the bid sits below break-up value, the price is too low, and the board can say so with arithmetic instead of adjectives.

Activists use the same math. They buy a stake, publish a sum-of-the-parts case, and press management to separate the pieces. The argument is simple. Your cloud arm is buried inside a slow industrial business, and the market pays for the whole at the discount of the worst part.

The break-up itself comes in flavors. A spin-off hands shareholders shares in the unit. A split-off lets them swap parent shares for unit shares. A carve-out sells a minority stake through an IPO. Each route asks the same question: is the whole worth more than the parts?

Then comes the cost of doing it. Separated divisions lose shared services, so overhead rises and some synergies vanish. And a spin-off can trigger the spinoff tax, a bill for shareholders the paper value never shows. SOTP prices the pieces, not the exit.

The hidden value in a conglomerate

Here is the edge SOTP gives you. A conglomerate can trade below the sum of its parts, a gap called break-up value. When the whole is worth less than the pieces, you have hidden value.

Investors often miss this, seeing one stock price instead of the parts. SOTP forces you to look at each business separately, which is how you spot a bargain before the market does. A buyer may break the company apart, so break-up value matters to activists.